Biotime (BTIM) reported (3/10/10) a FY09 net loss $5.14 M or $0.18 per diluted share compared to a $3.8 M or $0.16 per diluted share in FY08 .
- The increase in net loss for FY09 is largely attributable to increased R&D costs as BTIM expanded its stem cell research program and interest on borrowings under its Revolving Line of Credit Agreement (RLOCA), which has since been paid off.
Read more…
We are all looking for any signal that will propel a stock and ONE indicator is the CEO investing his own money in ASTMD. CEO’s “direct” share ownership should be a factor of significance, but should not be confused with option or grant holdings.
Timothy Mayleben, the new CEO filed a Form 4, this week with the SEC. Click: http://shareholder.api.edgar-online.com/efx_dll/edgarpro.dll?FetchFilingRTF1?sessionid=Qo_lHI3CLLNX2-D&ID=7112064&PageBreakStyleID=2
CEO’s can talk all they want about confidence in their future prospects and platforms, but the best vote of leadership is putting their percentage of their net worth on the line just like their investors!
Read more…
Opexa Therapeutics reported (3/5/10) a net loss of $1.43 M or $0.11 per diluted share for FY09 compared to $11.85 M or $1.12 per diluted share in FY08. FY09 highlights:
- The pivotal point in the year was the completion of the stem cell transaction with Novartis (NVS) Pharmaceuticals for an upfront payment of $3 M and potential technology transfer milestone payments totaling another $1 M (with total potential payments from the deal that could exceed $50 M),
Read more…
ASTMD reported the final patient treatment in the ongoing cardiac regeneration US P 2 surgical clinical trial designated IMPACT-DCM. Treated at Emory University Hospital Midtown in Atlanta, GA, this patient received direct injections of ASTMD’s tissue repair cells for the treatment of dilated cardiomyopathy (DCM), a severe form of congestive heart failure in which the heart becomes weakened and enlarged and cannot pump blood efficiently.
- With the treatment of the final patient in this trial, Aastrom is positioned to report 6 month interim data on all enrolled patients in late 2010.
Read more…
ASTMD has regained compliance with the $1.00 minimum bid price requirement under the NASDAQ Listing Rule.
- On 2/18/10, ASTMD affected a reverse stock split to increase the per-share trading price of its common stock to meet the NASDAQ requirement,
- The ticker symbol for Aastrom Biosciences will revert from ASTMD to ASTM on 3/18/10.
ASTMD reported results (2/24/10) from interim analysis of the multi-center, randomized, double-blind, placebo-controlled U.S. Phase 2b clinical trial designated RESTORE-CLI.
Read more…
Geron’s (GERN) collaboration with Corning launches Synthemax™ surface, a novel synthetic surface supporting the growth and differentiation of stem cells and growing hESCs.
- Industrial production of human embryonic stem cells (hESCs) can be problematic because the surface coating on which they are usually grown are expensive; subject to variability thus needing to be tested to ensure they are pathogen-free,
- Synthemax is designed to provide a synthetic contaminant growth matrix that supports the stable proliferation of undifferentiated hESCs in quantities suitable for cell therapy production,
- The advantage of this technology is that it can support cell differentiation after multiple passages.
Read more…
PSTI (3/2/10) received approval from an independent Data Safety Monitoring Board (DSMB) to advance its placenta-derived cell therapy product, PLX-PAD.
- This Phase I study in the EU is to evaluate the safety of PLX-PAD for 3 dosing levels in 15 patients for the treatment of Critical Limb Ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Read more…
The FDA has granted Orphan Drug designation for Advanced Cell Technology‘s (ACTC.OB) MA09-hRPE cells for use in the treatment of Stargardt’s Macular Dystrophy (SMD).
- As a result, ACTC.OB is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as 7 years.
Read more…
Merck KGaA agreed to buy Millipore (MIL), a supplier of drug-development equipment for biotechnology companies for about $6 B in cash, beating a rival offer from Thermo Fisher Scientific. BTIM’s ACTCellerate™ progenitor cell lines and ESpan™ cell growth media sell through MIL. Merck KGaA will pay $107 a share and is a Germany based company. The offer is 13 % more than Millipore’s closing price on 2/26/10 and 50 % higher. Millipore, based in Billerica, Massachusetts, put itself up for sale after getting an unsolicited takeover bid worth less than $95 a share from Thermo Fisher (Bloomberg).
Read more…
GERN reported a Q4/09 net loss of $18.4 M, or $0.20 a share based on higher operating expenses. FY09’s loss was $70.4 M, or $0.80 a share. Q4/09 revenue was $605 K, with $1.7 M in revenue for FY09. Revenues in 2009 reflected royalty and license fee revenue and collaboration funding from various agreements. GERN in Q4 had operating expenses of $19 M, with R&D expenses of $15.3 M which increased primarily due to higher non-cash compensation expense for equity-based awards. Q4 G&A expenses were $3.6 M with FY09 operating expenses finishing at $72 M. Shares of Geron fell $0.25, or 4.3 % to $5.55 in Friday’s trading. Shares have traded between $3.67 and $9.24 over the last 52 weeks. Don’t count GERN down and out with $178.62 M in cash!
The biggest issue in Q4/09 … was the FDA placing Geron’s IND for GRNOPC1 (a cell therapy for neurologically complete, sub-acute spinal cord injury) on clinical hold after GERN notified the agency of additional preclinical animal study data.
Read more…
